BR9904150A - Composições de proteìnas estabilizadas - Google Patents
Composições de proteìnas estabilizadasInfo
- Publication number
- BR9904150A BR9904150A BR9904150-2A BR9904150A BR9904150A BR 9904150 A BR9904150 A BR 9904150A BR 9904150 A BR9904150 A BR 9904150A BR 9904150 A BR9904150 A BR 9904150A
- Authority
- BR
- Brazil
- Prior art keywords
- protein compositions
- stabilized protein
- mammals
- stabilized
- csf
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 241000124008 Mammalia Species 0.000 abstract 3
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 abstract 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 101000746370 Bos taurus Granulocyte colony-stimulating factor Proteins 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 239000007995 HEPES buffer Substances 0.000 abstract 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 abstract 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 abstract 1
- 239000007994 TES buffer Substances 0.000 abstract 1
- 239000007997 Tricine buffer Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000004396 mastitis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçõES DE PROTEìNAS ESTABILIZADAS"<D>. Esta invenção refere-se à composições de proteínas estabilizadas, métodos para preparação de tais composições de proteínas estabilizadas, formas de dosagem para administração de tais composições de proteínas estabilizadas a mamíferos e métodos para prevenção ou tratamento em mamíferos através da administração de tais composições de proteínas a mamíferos. Mais particularmente, as composições de proteínas estabilizadas da presente invenção contem quantidades terapeuticamente eficazes de G-CSF, tal como o G-CSF bovino, em combinação com um tampão estabilizador, tais como HEPES, TES ou TRICINE, para o tratamento e prevenção de infecções, incluindo mastite em gado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9687698P | 1998-08-17 | 1998-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9904150A true BR9904150A (pt) | 2000-12-26 |
Family
ID=22259521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9904150-2A BR9904150A (pt) | 1998-08-17 | 1999-08-17 | Composições de proteìnas estabilizadas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050232898A1 (pt) |
| EP (1) | EP0988861B1 (pt) |
| JP (1) | JP3641170B2 (pt) |
| CN (1) | CN1250282C (pt) |
| AR (1) | AR016504A1 (pt) |
| AT (1) | ATE260674T1 (pt) |
| AU (2) | AU767431B2 (pt) |
| BR (1) | BR9904150A (pt) |
| CA (1) | CA2280449A1 (pt) |
| DE (1) | DE69915204T2 (pt) |
| DK (1) | DK0988861T3 (pt) |
| ES (1) | ES2216447T3 (pt) |
| NZ (2) | NZ510140A (pt) |
| PT (1) | PT988861E (pt) |
| TW (1) | TWI221773B (pt) |
| ZA (1) | ZA995201B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1129720E (pt) * | 2000-02-29 | 2004-08-31 | Pfizer Prod Inc | Factor estimulador de colonias de granulocitos estabilizado |
| JP5052736B2 (ja) * | 2001-05-30 | 2012-10-17 | 中外製薬株式会社 | タンパク質製剤 |
| ITMI20021684A1 (it) * | 2002-07-29 | 2004-01-29 | Therapicon Srl | Composizione farmaceutica di peptide nasale |
| ITBA20020032A1 (it) * | 2002-09-24 | 2004-03-25 | Bio D Soc | Metodo per stabilizzare le proteine per la conservazione ad alte temperature. |
| EP1641484A2 (en) * | 2003-05-09 | 2006-04-05 | Schering Aktiengesellschaft | Treatment of inflammatory respiratory diseases |
| US7585496B2 (en) | 2003-11-04 | 2009-09-08 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition granulocyte-colony stimulating factor |
| EP1537876A1 (en) * | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Erythropoietin solution formulation |
| EP1691798A1 (en) * | 2003-12-09 | 2006-08-23 | Alcon, Inc. | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
| RU2413530C9 (ru) * | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| PT1787658E (pt) * | 2005-11-10 | 2012-06-22 | Chemi Spa | Formulações de libertação sustentada de análogos de somatostatina inibidores da hormona do crescimento |
| DE202006020194U1 (de) | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
| US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| AU2008291309B2 (en) | 2007-08-27 | 2013-10-17 | Ratiopharm Gmbh | Liquid formulation of G-CSF |
| US8147968B2 (en) * | 2007-10-09 | 2012-04-03 | Hercules Incorportated | Diluents for crosslinker-containing adhesive compositions |
| PT2318029T (pt) * | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
| TWI480288B (zh) * | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| ITMI20120338A1 (it) * | 2012-03-06 | 2013-09-07 | Dr Andrea Bignotti | Preparato terapeutico e procedimento di preparazione di detto preparato terapeutico |
| GB2516808A (en) * | 2013-05-31 | 2015-02-11 | Innova Biosciences Ltd | Antibody composition and buffer system therefor |
| US11464831B2 (en) | 2015-01-05 | 2022-10-11 | Cornell University | Compositions and methods using IL-8 for improving health of mammals |
| RU2682318C2 (ru) | 2015-01-05 | 2019-03-19 | Корнелл Юниверсити | Композиции и способы для улучшения молочной продуктивности и репродуктивного здоровья млекопитающих, основанные на применении IL-8 |
| ES2952744T3 (es) | 2016-12-15 | 2023-11-03 | Nestle Sa | Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía |
| EP3771463A1 (en) | 2019-07-29 | 2021-02-03 | Ludwig-Maximilians-Universität München | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances |
| CN116836920B (zh) * | 2023-08-21 | 2024-05-24 | 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 | 一种无血清培养基及其制备间充质干细胞的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080879B1 (en) * | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
| JPS6069037A (ja) * | 1983-09-26 | 1985-04-19 | Sunstar Inc | エリテマト−デス治療用外用剤 |
| US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
| JPH0618781B2 (ja) * | 1986-10-18 | 1994-03-16 | 中外製薬株式会社 | 感染症治療剤 |
| JP2796388B2 (ja) * | 1988-05-13 | 1998-09-10 | アムジエン・インコーポレーテツド | Ｇ−ｃｓｆの精製方法 |
| US5013714A (en) * | 1988-12-15 | 1991-05-07 | Lindstrom Richard L | Viscoelastic solution |
| US6066469A (en) * | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
-
1999
- 1999-08-06 ES ES99306262T patent/ES2216447T3/es not_active Expired - Lifetime
- 1999-08-06 EP EP99306262A patent/EP0988861B1/en not_active Expired - Lifetime
- 1999-08-06 DK DK99306262T patent/DK0988861T3/da active
- 1999-08-06 AT AT99306262T patent/ATE260674T1/de not_active IP Right Cessation
- 1999-08-06 DE DE69915204T patent/DE69915204T2/de not_active Expired - Fee Related
- 1999-08-06 PT PT99306262T patent/PT988861E/pt unknown
- 1999-08-11 TW TW088113760A patent/TWI221773B/zh not_active IP Right Cessation
- 1999-08-13 CA CA002280449A patent/CA2280449A1/en not_active Abandoned
- 1999-08-13 AR ARP990104080A patent/AR016504A1/es active IP Right Grant
- 1999-08-16 AU AU44501/99A patent/AU767431B2/en not_active Ceased
- 1999-08-16 NZ NZ510140A patent/NZ510140A/en unknown
- 1999-08-16 NZ NZ337258A patent/NZ337258A/en unknown
- 1999-08-16 ZA ZA9905201A patent/ZA995201B/xx unknown
- 1999-08-17 BR BR9904150-2A patent/BR9904150A/pt not_active Application Discontinuation
- 1999-08-17 CN CNB99122020XA patent/CN1250282C/zh not_active Expired - Fee Related
- 1999-08-17 JP JP23085399A patent/JP3641170B2/ja not_active Expired - Fee Related
-
2004
- 2004-02-13 AU AU2004200568A patent/AU2004200568A1/en not_active Abandoned
-
2005
- 2005-06-01 US US11/143,340 patent/US20050232898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004200568A1 (en) | 2004-03-11 |
| EP0988861B1 (en) | 2004-03-03 |
| DK0988861T3 (da) | 2004-04-19 |
| DE69915204D1 (de) | 2004-04-08 |
| JP3641170B2 (ja) | 2005-04-20 |
| CA2280449A1 (en) | 2000-02-17 |
| HK1026151A1 (en) | 2000-12-08 |
| AU4450199A (en) | 2000-03-09 |
| US20050232898A1 (en) | 2005-10-20 |
| TWI221773B (en) | 2004-10-11 |
| EP0988861A1 (en) | 2000-03-29 |
| AR016504A1 (es) | 2001-07-04 |
| PT988861E (pt) | 2004-06-30 |
| NZ510140A (en) | 2005-01-28 |
| NZ337258A (en) | 2001-04-27 |
| JP2000063264A (ja) | 2000-02-29 |
| CN1250668A (zh) | 2000-04-19 |
| CN1250282C (zh) | 2006-04-12 |
| ATE260674T1 (de) | 2004-03-15 |
| AU767431B2 (en) | 2003-11-13 |
| ZA995201B (en) | 2001-02-16 |
| ES2216447T3 (es) | 2004-10-16 |
| DE69915204T2 (de) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9904150A (pt) | Composições de proteìnas estabilizadas | |
| AP9801420A0 (en) | Novel macrolides. | |
| BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
| BRPI0411016A (pt) | composições antisépticas, processos e sistemas | |
| BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
| PA8486001A1 (es) | Composiciones de celecoxib | |
| PT1131065E (pt) | Fumaratos dialquilicos para o tratamento de doencas autoimunes | |
| BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
| DE69833377D1 (de) | Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| PT806941E (pt) | Composicoes anti-bacterianas liposomicas de rigidez baixa | |
| BR0013010A (pt) | Formulação de cloreto de sódio de moxifloxacina | |
| BRPI0408407A (pt) | composto, composição farmacêutica, método de tratamento ou prevenção de dor, uso de um composto, e, processo para produzir um composto | |
| BR0215650A (pt) | Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica | |
| BR9914419A (pt) | Terapia para melhoria da percepção | |
| DE69637178D1 (de) | N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren | |
| BR9813317A (pt) | Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto | |
| BR0110382A (pt) | Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos | |
| BR9911917A (pt) | Composições compreendendo análogos de gaba e cafeìna | |
| BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
| BR9916432A (pt) | Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma | |
| PT817646E (pt) | Metodos de tratamento da inflamacao e formulacoes para esse fim | |
| BR9908522A (pt) | Composto, pró-droga, intermediário para a preparação de um composto, composição farmacêutica, processos para tratar e prevenir infecção por pneumovìrus, para tratar células em cultura, para tratar materiais biológicos, e, para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO, A REQUERENTE DEVERA COMPLEMENTAR O VALOR DA TAXA DE EXAME REFERENTE A 2 (DUAS) REIVINDICACOES EXCEDENTES QUE FORAM APRESENTADAS ATRAVES DA PETICAO NO 037754 DE 12/07/2002. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |